Welcome to our dedicated page for Polypid Ltd. SEC filings (Ticker: PYPD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sifting through PolyPid’s clinical-stage biotech disclosures can feel like navigating surgical protocol—hundreds of pages on PLEX technology, cash runway, and FDA milestones. If you’ve wondered, “How do I decode a PolyPid annual report 10-K simplified or track PolyPid insider trading Form 4 transactions before pivotal data?” you’re not alone. Complex risk factors, trial endpoints, and dilution clauses make these SEC documents essential yet daunting.
Stock Titan’s AI-powered analysis turns that complexity into clarity. Every filing—whether a PolyPid quarterly earnings report 10-Q filing, a rapid-fire 8-K material events update, or a proxy statement on executive compensation—is parsed in real time. Our platform highlights where D-PLEX100 trial costs hit the income statement, flags liquidity warnings, and delivers Form 4 insider transactions real-time so you immediately spot executive stock transactions Form 4 that might precede major announcements. Need context? Our AI summaries answer natural questions like “PolyPid SEC filings explained simply” or “understanding PolyPid SEC documents with AI,” saving hours of manual review.
Investors rely on this page to:
- Monitor cash burn and funding plans disclosed in 10-Qs
- Catch PolyPid earnings report filing analysis without reading footnotes
- Stay alert to PolyPid 8-K material events explained—such as Phase-3 trial readouts
- Examine PolyPid proxy statement executive compensation to assess alignment
PolyPid Ltd. disclosed that Aurum Ventures M.K.I. Ltd. and Morris Kahn each report beneficial ownership of 5,001,561 ordinary shares, representing 28.1% of the class on a fully-diluted basis that counts 1,918,879 shares issuable upon exercise of currently exercisable warrants. The filing clarifies that the reported totals do not give effect to warrant "blocker" provisions that prevent exercises that would raise beneficial ownership above 9.9% at any given time, so the actual number of shares that can be owned simultaneously is lower than the aggregate reported.
The statement explains that Mr. Kahn is the ultimate sole beneficiary of Aurum and may be deemed to share beneficial ownership of the shares held by Aurum, while disclaiming day-to-day voting or investment control over Aurum-held shares.
PolyPid Ltd. submitted a Form 6-K dated August 13, 2025, furnishing its unaudited interim condensed financial statements and management's discussion and analysis for the six months ended June 30, 2025. The filing includes XBRL-formatted financial information covering interim condensed consolidated balance sheets, statements of operations, shareholders' equity, cash flows and notes, plus an embedded Cover Page Interactive Data File. The report is submitted by the Chief Executive Officer and lists related exhibit numbers for the financial statements, MD&A and XBRL tagging.
PolyPid Ltd. filed a Form S-8 to register 1,200,000 additional ordinary shares for issuance under the Amended and Restated 2012 Share Option Plan, incremental to 2,311,570 shares previously registered. The Registration Statement incorporates by reference the Company's Annual Report on Form 20-F for the fiscal year ended December 31, 2024 and specified Form 6-K reports that include recent financial results for the quarters and six-month periods ended June 30, 2025.
The company's amended articles will permit exemption, indemnification and insurance of officers to the fullest extent allowed under Israeli law; PolyPid intends to obtain directors and officers liability insurance and to enter into indemnification and exemption agreements with officers, while noting the SEC view that indemnification against Securities Act liabilities is unenforceable. The filing indicates the company is an emerging growth company and a non-accelerated filer.
Rosalind Advisors, related individuals and a fund report collective beneficial ownership of 5,762,349 common shares of PolyPid Ltd., representing 9.9% of the outstanding common stock based on 15,897,201 shares outstanding per the issuer's disclosure. The reported position consists of 975,462 shares of Common Stock and 4,786,887 shares issuable upon exercise of warrants.
The filings show shared voting and dispositive power over 5,762,349 shares and no sole voting or dispositive power. The warrants include a blocker provision that prevents exercise to the extent it would increase beneficial ownership above 9.99%, and the filing states actual ownership after giving effect to those blockers is less than the amounts reported.